Nexalin Technology (NXL) Return on Sales (2021 - 2026)

Nexalin Technology's Return on Sales history runs 6 years deep, the most recent figure standing at 1.4% for Q1 2026.

• On a quarterly basis, Return on Sales fell 92.0% year-over-year to 1.4% in Q1 2026; TTM through Mar 2026 was 0.3%, a 35.0% increase from a year earlier, with the FY2025 full-year figure at 0.22%, up 24.0% from the prior year.
• Return on Sales declined to 1.4% in Q1 2026 per NXL's latest filing, from 0.14% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q3 2022 and bottomed at 1.4% in Q1 2026.
• The 5-year median for Return on Sales is 0.24% (2023), against an average of 0.46%.
• Across the five-year window, Return on Sales slumped 95 bps in 2023 and soared 90 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.2% in 2022, then sank by 91 bps to 0.38% in 2023, then plunged by 174 bps to 1.04% in 2024, then surged by 87 bps to 0.14% in 2025, then tumbled by 914 bps to 1.4% in 2026.
• Per Business Quant, the three latest NXL Return on Sales figures stand at 1.4% (Q1 2026), 0.14% (Q4 2025), and 1.25% (Q3 2025).